The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows ...

A recent Chinese clinical trial published in The BMJ reveals that dapagliflozin, a type 2 diabetes drug, shows promise in ...

More than 15 million people across the US, UK, Germany and France are unknowingly living with metabolic ...

Metabolic dysfunction–associated steatohepatitis (MASH) is the new term for non-alcoholic steatohepatitis (NASH). There are ...

Currently, the only approved treatment for MASH on the market is the thyroid hormone receptor β agonist resmetirom (Rezdiffra ...

NASH becomes MASH as medical experts replace stigmatizing "non-alcoholic" liver disease terminology with dignity-focused ...

A new American Diabetes Association consensus statement provides guidance on screening, diagnosing, and managing metabolic ...

Improves fibrosis and steatohepatitis Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses a broad clinical spectrum, ranging from simple steatosis to metabolic ...

An international study reveals that the drug can reverse liver damage in patients. An international study led by researchers ...

New technology and drugs are transforming how doctors detect and treat silent liver disease MASLD before it leads to liver ...

Fat cells are also metabolically active and can cause a chronic state of inflammation in the part of the body where they ...

High levels of liver enzymes in your blood may sometimes indicate an underlying liver condition that requires medical ...